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Original Research Articles–Clinical

Free and Bioavailable 25-Hydroxyvitamin D Concentrations are
Associated With Disease Activity in Pediatric Patients With Newly
Diagnosed Treatment Naïve Ulcerative Colitis
Cary G. Sauer, MD, MSc,* Matthew S. Loop, PhD,† Suresh Venkateswaran, MD,* Vin Tangpricha, MD,*
Thomas R. Ziegler, MD,* Ashish Dhawan, MD,‡ Courtney McCall, BS,§ Erin Bonkowski, BS,§ David R. Mack, MD,¶
Brendan Boyle, MD,** Anne M. Griffiths, MD,†† Neal S. Leleiko, MD,‡‡ David J. Keljo, MD,§§ James Markowitz, MD,¶¶
Susan S. Baker, MD,*** Joel Rosh, MD,††† Robert N. Baldassano, MD,‡‡‡ Sonia Davis, DrPH,† Shiven Patel,*
Jessie Wang, MS,† Alison Marquis, MStat,† Krista L. Spada, BS,§§§ Subra Kugathasan, MD,* Thomas Walters, MD,††
Jeffrey S. Hyams, MD§§§ and Lee A. Denson, MD§

Background: Vitamin D regulates intestinal epithelial and immune functions, and vitamin D receptor deficiency increases the severity of murine
colitis. Bioavailable 25-hydroxyvitamin D (25(OH)D) is available to target tissues and may be a driver of immune function. The aim is to evaluate
the relationship of bioavailable 25(OH)D to the clinical expression of treatment naive pediatric ulcerative colitis (UC).
Methods: The PROTECT (Predicting Response to Standardized Pediatric Colitis Therapy) study enrolled children ≤17 years newly diagnosed
with UC. Free and total 25(OH)D were directly measured and 25(OH)D fractions were compared with disease activity measures.
Results: Data were available on 388 subjects, mean age 12.7 years, 49% female, 84% with extensive/pancolitis. The median (IQR) total 25(OH)
D concentration was 28.5 (23.9, 34.8) ng/mL, and 57% of subjects demonstrated insufficient vitamin D status (25(OH)D < 30 ng/mL). We found
no evidence of association between total 25(OH)D and disease activity. Regression models adjusted for age, sex, race, and ethnicity demonstrated
that an increase from 25th to 75th percentile for bioavailable and free 25(OH)D were associated with a mean (95th CI) decrease in the Pediatric
Ulcerative Colitis Activity Index (PUCAI) of -8.7 (-13.7, -3.6) and -3.1 (-5.0, -1.2), respectively. No associations were detected between 25(OH)D
fractions and fecal calprotectin or Mayo endoscopy score.

Conclusions: Vitamin D insufficiency is highly prevalent in children with newly diagnosed UC. We found associations of free and bioavailable,
but not total 25(OH)D, with PUCAI. Bioavailable vitamin D may contribute to UC pathophysiology and clinical activity.

Key Words: pediatric, inflammatory bowel disease, ulcerative colitis, vitamin D
What is Known/What is New
What is Known
•
•
•

Vitamin D deficiency is common in pediatric UC patients.
Vitamin D regulates intestinal epithelial and immune functions.
Vitamin D receptor deletion in mice exacerbates experimental colitis.

What is New
•

Free and bioavailable 25(OH) vitamin D but not total 25(OH)
D are associated with disease activity as defined by the Pediatric
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•

Ulcerative Colitis Activity Index (PUCAI) in treatment naive pediatric UC patients.
Bioavailable 25(OH)D may play a role in the pathogenesis of pediatric UC.

INTRODUCTION
Crohn’s disease (CD) and ulcerative colitis (UC) are
relapsing and remitting disorders of the gastrointestinal tract
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characterized by acute and chronic inflammation leading to
mucosal injury.1 Current evidence suggests that a complex interplay between the intestinal microbiota, intestinal epithelia, and
innate and adaptive immune systems drives disease pathogenesis.2
Emerging data over the past decade have suggested that vitamin
D plays a significant role in both epithelial and immune system
dysregulation in this setting, leading to practice guidelines for
supplementation.3–5 These studies have been limited by measurement of only total serum 25-hydroxvitamin D (25(OH)D), which
reflects total body stores, but may not adequately define the bioavailable pool exerting beneficial effects in the gut.6 For example,
recent studies have demonstrated a stronger association between
bioavailable 25(OH)D than total serum 25(OH)D for markers of
bone mineral metabolism.7 Whether this would also be the case
for measures of disease activity in UC was not known.
Vitamin D has an established role in bone health and calcium homeostasis. However, both intestinal epithelial cells (IEC)
and a wide variety of immune cells also possess the vitamin D
receptor (VDR), suggesting a role for vitamin D in regulation of
IECs and the immune system. The VDR has been identified on
multiple types of immune cells including T-helper cells (CD4+),
cytotoxic T-cells (CD8+), B cells, neutrophils, dendritic cells, and
macrophages.8 Thus, there is a growing body of literature that suggests vitamin D has a role not only in bone health and calcium
homeostasis, but also a significant role in immune system function.
A recent meta-analysis demonstrated that adult-onset IBD
patients were more than twice as likely to be vitamin D deficient
as healthy controls.9 A recent pediatric study demonstrated IBD
patients with an elevated sedimentation rate had a significantly
lower 25(OH)D compared to controls.10 With one exception, IBD
studies to date have evaluated only total 25(OH)D.11 However,
only a small portion (5%–10%) of total 25(OH)D is bioavailable and thus free to diffuse into cells to bind the VDR, with the
rest bound to vitamin D-binding protein (VDBP).6 Bioavailable
vitamin D includes the free 25(OH)D and albumin-bound vitamin
D fractions. It is this bioavailable vitamin D that is available to
target tissues and is more likely to play a significant role in IEC
and immune system regulation. Prior efforts to define bioavailable
vitamin D have been limited by indirect methods that involved
measurement of vitamin D-binding protein (VDBP) and likely
overestimated the bioavailable vitamin D pool. With the recent
availability of a method to directly measure free vitamin D and
thereby precisely calculate bioavailable vitamin D, we sought to
understand the relationship between free and bioavailable vitamin
D and disease activity in a large pediatric UC inception cohort.
The PROTECT Study: Predicting Response to Standardized
Pediatric Colitis Therapy was initiated in 2012 to systematically
examine the response of children and adolescents newly diagnosed with UC to standardized treatment regimens. During this
prospective study, a large inception patient cohort was rigorously
phenotyped clinically and endoscopically. We now report the relationship between free and bioavailable vitamin D and disease
activity in this large pediatric UC inception cohort.
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METHODS
PROTECT Study
The PROTECT enrolled 428 children with UC between
the ages of 4 and 17 at diagnosis, before therapy, at 26 participating sites in North America. The study was approved by the
Institutional Review Boards at each of the sites, and informed
consent was obtained for each of the participants, with assent
obtained for those age 11 and older. Demographic, clinical, laboratory, and endoscopic findings at diagnosis were recorded and
only patients with a confirmed diagnosis of UC were included.
Inclusion criteria included clinical symptoms (abdominal pain,
loose stools, and rectal bleeding), a negative stool infectious
workup, and endoscopic/histologic confirmation of UC based
on established criteria with disease extending beyond the rectum. The current analysis included 388 participants with complete data for free, bioavailable, and total vitamin D fractions.

Determination of Vitamin D Fractions
Plasma collected at diagnosis before therapy was used to
measure free 25(OH)D, total 25(OH)D, and albumin to determine vitamin D status. Total 25(OH)D was measured using
the IDS-iSYS 25-Hydroxyvitamin D automated chemiluminescense immunoassay (Gaithersburg, MD) in a laboratory
participating in the Vitamin D External Quality Assessment
Scheme (DEQAS) and the NIST/NIH Vitamin D Quality
Assurance Program (VitDQAP). The plasma free 25(OH)D
was assayed by ELISA (DIAsource ImmunoAssays, Louvainla-Neuve, Belgium)12
Albumin was measured at a central laboratory by ELISA
per manufacturer’s instructions (Cell Biolabs, Inc., San Diego,
CA) for participants with no available clinical value (40 patients).
Bioavailable vitamin D ([Bio D]) was calculated from
measured free vitamin D and measured albumin using the following formula.13
[Bio D] = [DFree] + [DAlb]
[DAlb] = concentration of albumin-bound
25-hydroxyvitamin D
[DFree] = concentration of free (unbound)
25-hydroxyvitamin D
[DAlb] = Kalb· [Total Serum Albumin] · [DFree]
Kalb = affinity constant between 25-hydroxyvitamin
D and albumin = 6 × 105 M-1
Fecal calprotectin was performed centrally by ELISA
per manufacturer’s instructions (Buhlmann Laboratories AG,
Schönenbuch, Switzerland) from stool samples collected before
colonoscopy cleanout or ≥2 days after colonoscopy but not
more than 3 days after initial UC treatment The assay has a
sensitivity of 10 mcg/gm with a standard range of 30 mcg/gm
to 1800 mcg/gm. Samples above the standard range underwent
serial dilution. The intraassay precision is 2.7% to 8.1%, and
the interassay precision is 6.6% to 14.5%.
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Statistical Analysis
We calculated summary statistics of 25(OH)D fractions
(total, bioavailable, and free) in the total sample and tested for
pairwise associations between the vitamin D fractions using
the Spearman correlation test. We calculated summary statistics of demographics, clinical and laboratory measures, and
disease activity (PUCAI and Mayo endoscopy subscore as
determined by the site clinical investigator) in the total sample
and by clinical cutpoints of total vitamin D (deficient was
<20 ng/mL, insufficient was 20 to <30 ng/mL, and sufficient
was ≥30 ng/mL) and by tertiles of bioavailable and free 25(OH)
D. We conducted univariate tests of association between participant baseline characteristics and these vitamin D categories using ANOVA for Gaussian-distributed variables, the
Kruskal-Wallis test for skewed continuous variables, the mean
score chi-square test for nonordered categorical (ie, nominal)
variables, and the nonzero correlation test for ordinal variables.
We used linear regression to fit models for the unadjusted
relationship between PUCAI and log10 of the vitamin D fractions. Nonlinear relationships between PUCAI and 25(OH)
D fractions were tested for using restricted cubic splines with
5 knots, with F-tests for the nonlinear model terms.14 If the
hypothesis tests for the nonlinear model terms were not statistically significant at the alpha = 0.05 level, then the nonlinear
terms were dropped from the model. We fit additional models for
each fraction of 25(OH)D that were adjusted for age, sex, race,
and Hispanic ethnicity as potential confounders. As sensitivity
analyses, unadjusted and adjusted models were also fit for: (1)
the relationship between Mayo endoscopy subscore (severe/moderate vs mild) and 25(OH)D fraction using logistic regression;
and (2) the relationship between fecal calprotectin and 25(OH)
D fraction using linear regression. We reported mean differences
with 95% confidence intervals for the difference between the 1st
and 3rd quartile of the 25(OH)D fraction when modeling PUCAI
and fecal calprotectin and odds ratios with 95% confidence intervals when modeling Mayo endoscopy subscore.

RESULTS
Demographic Characteristics of the Cohort
A total of 388 subjects with complete data for 25(OH)
D fractions were included in the analysis. All subjects were
enrolled at initial diagnosis of UC with clinical and laboratory
measures obtained before therapy. The mean age of diagnosis was 12.7 years with 49% female. The sample was predominantly white (81%) but included Asians (5%) and blacks (7%)
and 9% of the participants self-identified as Hispanic (Table 1).

Clinical and Laboratory Characteristics
The median (IQR) PUCAI for the patient population
was 50 (35,65) with 129 (33%) patients demonstrating severely
active colitis defined by a PUCAI ≥65, and 167 (43%) patients
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demonstrating moderately active disease defined by a PUCAI between 35 and 60. The Mayo endoscopy subscore similarly demonstrated endoscopically severe Mayo 3 disease in 132 (34%) patients
and moderate Mayo 2 disease in 206 (53%) patients. A total of
325 (84%) patients presented with extensive or pancolitis disease
location (Table 1). The median hemoglobin was 11.6 g/dL, the median erythrocyte sedimentation rate (ESR) was 24 mm/hour, and
the median albumin was 3.8 g/dL. C-reactive protein (CRP) was
greater than 2X the upper limit of normal in 88 (30%) patients.
The median fecal calprotectin was 2286 mcg/g, with 176 of the
222 subjects (79%) having baseline stool calprotectin >1000 mcg/g.

Vitamin D Status of Participants
The median (IQR) total 25(OH)D concentration was
28.5 (23.9,34.8) ng/mL with 166 (43%) patients demonstrating vitamin D sufficiency defined by a level greater than or
equal to 30 ng/mL. A total of 181 patients (47%) demonstrated vitamin D insufficiency defined as a level between 20
and 30 ng/mL and a total of 41 patients (11%) demonstrated
vitamin D deficiency defined as a level below 20 ng/mL. The
median (IQR) free vitamin D concentration was 4.1 (2.9,
6.0 pg/mL), and the median (IQR) bioavailable vitamin D
concentration was 1.3 (0.8, 1.9) ng/mL. We then tested for
associations between these vitamin D fractions. We observed
a moderate correlation between bioavailable 25(OH)D and
total 25(OH)D (Spearman correlation of 0.46, P < 0.01) and
between free 25(OH)D and total 25(OH)D (Spearman correlation of 0.49, P < 0.01) (Fig. 1A and B). As expected, we
confirmed a strong correlation between free and bioavailable
25(OH)D (Spearman r = 0.93, P < 0.01, Fig. 1C). Further
examination demonstrates a strong correlation between free
and bioavailable 25(OH)D within different categories of
total vitamin D (Supplemental Figure 1). Collectively, these
data demonstrated that bioavailable vitamin D represented
approximately 4.7% (3.1%, 6.5%) of the total vitamin D pool
within a newly diagnosed pediatric UC cohort, with a moderate correlation with total vitamin D levels.

Association between Total Vitamin D and
Bioavailable/free Vitamin D
We evaluated the linearity between bioavailable 25(OH)
D and total vitamin D and the linearity between free 25(OH)
D and total vitamin D. The relationship between bioavailable
25(OH)D and total 25(OH)D is positive until approximately
40 ng/mL of total 25(OH)D at which point there appears to
be no relationship, with similar findings for the relationship
between free 25(OH)D and total 25(OH)D. This data suggest
that as total 25(OH)D increases, free and bioavailable 25(OH)
D also increase, up to a total 25(OH) D level of 40 ng/mL, at
which any further increases in total 25(OH)D result in no additional increase in free or bioavailable 25(OH)D (Fig. 2).
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TABLE 1: Clinical and Demographic Characteristics by Total Vitamin D Clinical Cut Points
Total Vitamin D (ng/mL)
Variablea
Age, yearsb
Race
Asian
Black
Other
White
Females
Hispanic
Weight z-scoreb
Disease Location
Proctosigmoiditis
Left-sided colitis
Extensive / Pancolitis /
Unassessable
Albumin (g/dL)c
Hemoglobin (g/dL)c
ESR (mm/hr)c
CRP or hsCRP (mg/dL)
>ULN
>2 × ULN
Fecal calprotectin (mcg/g)c
PUCAIc
Mild (10–34)
Moderate (35–64)
Severe (≥65)
Mayo endoscopy subscore
Mild (1)e
Moderate (2)
Severe (3)

<20 ng/mL (n = 41)

20–<30 ng/mL
(n = 181)

12.7 (3.3)

13.7 (2.4)

13.0 (3.2)

12.2 (3.5)

0.009

18 (5%)
26 (7%)
28 (7%)
316 (81%)
191 (49%)
34 (9%)
-0.1 (1.1)

3 (7%)
5 (12%)
3 (7%)
30 (73%)
15 (37%)
4 (10%)
-0.3 (1.4)

14 (8%)
15 (8%)
15 (8%)
137 (76%)
97 (54%)
18 (10%)
-0.1 (1.1)

1 (1%)
6 (4%)
10 (6%)
149 (90%)
79 (48%)
12 (7%)
-0.0 (1.1)

0.001
0.01
0.29

23 (6%)
40 (10%)
325 (84%)

1 (2%)
7 (17%)
33 (80%)

19 (10%)
18 (10%)
144 (80%)

3 (2%)
15 (9%)
148 (89%)

0.04

3.9 (3.4, 4.2)
11.3 (9.9, 12.7)
28.5 (14.0, 42.0)

0.35
0.17
0.24

Total Sample (n = 388)

3.8 (3.2, 4.2)
11.6 (10.3, 12.9)
24.0 (12.0, 41.0)
129 (45%)
88 (30%)
2285.9 (1171.7, 3906.7)
50.0 (35.0, 65.0)
92 (24%)
167 (43%)
129 (33%)
50 (13%)
206 (53%)
132 (34%)

3.8 (3.3, 4.3)
11.7 (9.0, 13.0)
22.0 (12.5, 34.5)

3.7 (3.0, 4.2)
11.9 (10.5, 13.0)
23.0 (11.0, 44.0)

15 (42%)
6 (17%)
1891.1 (1157.1,
4181.1)
50.0 (30.0, 65.0)
11 (27%)
17 (41%)
13 (32%)

63 (46%)
45 (33%)
1798.6 (1071.0, 3849.9)

3 (7%)
22 (54%)
16 (39%)

45.0 (30.0, 65.0)
49 (27%)
70 (39%)
62 (34%)
26 (14%)
96 (53%)
59 (33%)

≥30 ng/mL (n = 166)

51 (44%)
37 (32%)
2633.8 (1388.5, 4008.8)
50.0 (40.0, 65.0)
32 (19%)
80 (48%)
54 (33%)
21 (13%)
88 (53%)
57 (34%)

P-valued

0.92
0.40
0.36

0.99
0.28
0.39
0.50
0.43

0.82

Values are n (%) unless otherwise specified; bmean (standard deviation); cmedian (quartile 1, quartile 3); dP-value for ANOVA when mean (standard deviation) is presented,
Kruskal-Wallis when median (quartile 1, quartile 3) is presented, mean score chi-square test for nominal row variables, and nonzero correlation test for ordinal row variables. For
race variable, p-value is for that racial group vs whites.
One participant with no disease evident was included in the mild group.
e
a

Association of Total Vitamin D and
Demographic/Clinical Characteristics
Patients were grouped by total 25(OH)D into 3 categories based on current clinical guidelines (sufficient, insufficient,
and deficient).3 Patients with vitamin D deficiency/insufficiency
were older at diagnosis than those with vitamin D sufficiency.
The distribution of total vitamin D categories also varied with
disease location, with extensive/pancolitis participants occurring more frequently in those with sufficient total vitamin
D. We did not find statistically significant evidence of associations between categories of total vitamin D and albumin,
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hemoglobin, ESR, CRP, fecal calprotectin, PUCAI, or Mayo
subscore (Table 1).

Association of Free and Bioavailable
Vitamin D Fractions and Demographic/
Clinical Characteristics
There are no standard clinical cut points for bioavailable 25(OH)D. Patients were therefore grouped according to
tertiles of bioavailable 25(OH)D. As with total 25(OH)D, the
oldest age-of-diagnosis was observed within the lowest tertile
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FIGURE 1. Spearman correlations between vitamin D fractions. A, Demonstrates moderate correlation between bioavailable and total 25(OH)
D (Spearman correlation of 0.46, P < 0.01, n = 388). B, Demonstrates moderate correlation between free 25(OH)D and total 25(OH)D (Spearman
correlation of 0.49, P < 0.01, n = 388). C, Demonstrates strong correlation between free and bioavailable 25(OH)D (Spearman r = 0.93, P < 0.01,
n = 388).

of bioavailable vitamin D (Table 2). Similarly, the distribution
of bioavailable 25(OH)D differed between whites and blacks,
with blacks more likely to be in the lowest tertile (≤1.02 ng/mL)
of bioavailable 25(OH)D. Similar associations with age and
race were observed when considering tertiles of free 25(OH)
D (Supplemental Table 1). The distribution of bioavailable
25(OH)D also varied with disease location, but in this case participants with extensive/pancolitis were more common in the
lowest tertile of bioavailable 25(OH)D. In terms of the laboratory parameters, albumin and hemoglobin were lower, and the
inflammatory markers ESR and CRP were higher, for participants within the lowest tertile of bioavailable 25(OH)D. A similar result was observed for free 25(OH)D, with participants
with lower albumin and hemoglobin in the lowest tertile of free
25(OH)D (Supplemental Table 1). There was no statistically significant evidence that fecal calprotectin or the Mayo endoscopy
subscore varied across the groups for either free or bioavailable

25(OH)D. However, consistent with the laboratory parameters,
the clinical measure of disease activity, PUCAI, was increased
in participants within the first or second tertiles of either free
or bioavailable 25(OH)D, compared to participants in the third
tertile (Table 2 and Supplemental Table 1).

Associations between Vitamin D Fractions and
Disease Activity
Linear regression model results for the associations
between vitamin D fractions and PUCAI are presented in
Table 3. Bioavailable vitamin D was modeled using restricted
cubic splines with 5 knots, whereas total 25(OH)D and free
25(OH)D were modeled using only linear terms, due to the
lack of significance of the nonlinear terms for these fractions
in preliminary models. All model results were reported for a
change from the 1st quartile to the 3rd quartile of the vitamin D
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FIGURE 2. Relationship between total vitamin D and bioavailable/free vitamin D. Results demonstrate a positive relationship between total 25(OH)
D and both free and bioavailable 25(OH)D until the total 25(OH)D reaches approximately 40 ng/ml.

fraction, due to the different measurement scales (ie, ng/mL
vs pg/mL). In models adjusted for age, race, sex, and Hispanic
ethnicity, a change from 23.9 ng/mL to 34.8 ng/mL in total
25(OH)D was not statistically significantly associated with a
change in PUCAI (mean difference [95% confidence interval]:
0.8 [-1.8, 3.5]). However, in models adjusted for the same potential confounders, a change in bioavailable 25(OH)D from
0.84 ng/mL to 1.94 ng/mL was associated with a mean difference in PUCAI of -8.7 (-13.7, -3.6) points, indicating a statistically significant inverse relationship. Finally, a change in
free 25(OH)D from 2.93 pg/mL to 5.96 pg/mL was statistically
significantly associated with a mean difference in PUCAI of
-3.1 (-5.0, -1.2) points. Predicted mean PUCAI and 95% confidence bands from these models are displayed in Figure 3,
demonstrating a statistically significant decrease in PUCAI
with increasing free and bioavailable 25(OH)D.
As sensitivity analyses, we also investigated the relationships between these vitamin D fractions and Mayo endoscopy
subscore (moderate/severe vs mild; Supplemental Table 2) and
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fecal calprotectin (Supplemental Table 3). Only the linear terms
for the vitamin D fractions were included in the models as
the nonlinear terms were not found to be statistically significant. No vitamin D fractions, either in unadjusted or adjusted
models, were significantly associated with Mayo endoscopy
subscore or fecal calprotectin. However, the results for this exploratory sensitivity analysis for fecal calprotectin should be
interpreted with caution due to extreme nonGaussian distributions of the model residuals that was not resolved via transformations of the model outcome, and the large fraction of
participants (43%) missing a fecal calprotectin measurement..
Collectively, these analyses suggested a statistically significant
association between increased free and bioavailable 25(OH)D
and decreased clinical disease activity in a large treatment naive
pediatric UC cohort.

DISCUSSION
To our knowledge we have conducted the first analysis of
the relationship between bioavailable 25(OH)D and measures
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TABLE 2: Clinical and Demographic Characteristics by Bioavailable Vitamin D Tertiles
Tertile of Bioavailable Vitamin D (ng/mL)
Variablea
Age, yearsb
Race
Asian
Black
Other
White
Females
Hispanic
Weight z-scoreb
Disease Location
Proctosigmoiditis
Left-sided colitis
Extensive / Pancolitis /
Unassessable
Albumin (g/dL)c
Hemoglobin (g/dL)c
ESR (mm/hr)c
CRP or hsCRP (mg/dL)
>ULN
>2 × ULN
Fecal calprotectin (mcg/g)c
PUCAI^
Mild (10–34)
Moderate (35–64)
Severe (≥65)
Mayo endoscopy subscore
Mild (1)e
Moderate (2)
Severe (3)

Total Sample
(n = 388)

Tertile 1 (n = 130)
≤1.02 ng/mL

Tertile 2 (n = 129)
>1.02–1.72 ng/mL

Tertile 3 (n = 129)
>1.72 ng/mL

P-valued

12.7 (3.3)

13.5 (2.9)

12.7 (3.3)

11.9 (3.6)

<0.001

18 (5%)
26 (7%)
28 (7%)
316 (81%)
191 (49%)
34 (9%)
-0.1 (1.1)

7 (5%)
18 (14%)
9 (7%)
96 (74%)
69 (53%)
13 (10%)
-0.2 (1.2)

6 (5%)
5 (4%)
8 (6%)
110 (85%)
67 (52%)
11 (9%)
-0.0 (1.2)

5 (4%)
3 (2%)
11 (9%)
110 (85%)
55 (43%)
10 (8%)
0.0 (0.9)

0.43
<0.001
0.85

23 (6%)
40 (10%)
325 (84%)

2 (2%)
10 (8%)
118 (91%)

10 (8%)
13 (10%)
106 (82%)

11 (9%)
17 (13%)
101 (78%)

0.01

3.8 (3.2, 4.2)
11.6 (10.3, 12.9)
24.0 (12.0, 41.0)

3.4 (2.8, 3.8)
10.8 (9.4, 12.3)
29.0 (15.0, 51.0)

3.9 (3.4, 4.2)
11.8 (10.5, 12.8)
26.5 (10.5, 44.0)

4.1 (3.7, 4.4)
12.1 (10.8, 13.3)
19.5 (10.0, 31.0)

<0.001
<0.001
0.001

129 (45%)
88 (30%)
2285.9 (1171.7,
3906.7)
50.0 (35.0, 65.0)
92 (24%)
167 (43%)
129 (33%)

56 (58%)
42 (43%)
2132.6 (1087.2, 4021.6)

46 (47%)
28 (29%)
3332.9 (1380.8, 4181.1)

27 (29%)
18 (19%)
1921.2 (1150.5, 3540.5)

<0.001
<0.001
0.14

57.5 (40.0, 75.0)
19 (15%)
51 (39%)
60 (46%)

50.0 (30.0, 65.0)
33 (26%)
53 (41%)
43 (33%)

45.0 (30.0, 60.0)
40 (31%)
63 (49%)
26 (20%)

<0.001
<0.001

50 (13%)
206 (53%)
132 (34%)

12 (9%)
65 (50%)
53 (41%)

18 (14%)
72 (56%)
39 (30%)

20 (16%)
69 (53%)
40 (31%)

0.09
0.52
0.14

0.05

Values are n (%) unless otherwise specified; bmean (standard deviation); cmedian (quartile 1, quartile 3); dP-value for ANOVA when mean (standard deviation) is presented,
Kruskal-Wallis when median (quartile 1, quartile 3) is presented, mean score chi-square test for nominal row variables, and nonzero correlation test for ordinal row variables. For
race variable, p-value is for that racial group vs whites.
One participant with no disease evident was included in the mild group.
e
a

of clinical and endoscopic disease activity in a large treatment
naive pediatric UC inception cohort. It is likely that biologic
effects of 25(OH)D on intestinal epithelial and immune cells
in UC are mediated by the free and albumin-bound fractions,
which together constitute bioavailable 25(OH)D. The recent
availability of a method to directly measure free vitamin D
afforded the opportunity to test this, whereas avoiding the
confounding introduced by prior approaches that relied on
estimates of human serum carrier proteins (VDBP) abundance
and binding affinity. We found that lower levels of both free and
bioavailable 25(OH)D, but not total 25(OH)D, were inversely

correlated with higher levels of clinical disease activity as measured by PUCAI. The association of bioavailable 25(OH)D with
disease activity supports this hypothesis and provides a basis
for future exploration into the wide-ranging effects of bioavailable vitamin D on the immune system and disease activity.
Fifty-seven percent of enrolled subjects were vitamin D
deficient or insufficient. Pappa et al reported similar findings
with 63.6% of 143 UC patients exhibiting a vitamin D concentration less than 32 ng/mL, 19.6% exhibiting a vitamin
D concentration less than 20 ng/mL, and a higher likelihood
of vitamin D deficiency in UC patients compared to CD
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TABLE 3: Linear Regression Models of First Tertile vs Third Tertile of Vitamin D Fractions and Associated Mean
Differences in PUCAI Score
Vitamin D fraction
Total vitamin D
Bioavailable vitamin D
Free vitamin D

Sample Size Used

Modelb

Difference in mean PUCAI Score
(95% Confidence Interval)a

P-value

388
384
388
384
388
384

Unadjusted
Adjusted
Unadjusted
Adjusted
Unadjusted
Adjusted

0.9 (-1.7, 3.4)
0.8 (-1.8, 3.5)
-8.4 (-13.3, -3.5)
-8.7 (-13.7, -3.6)
-2.9 (-4.7, -1.0)
-3.1 (-5.0, -1.2)

0.50
0.54
<0.001
<0.001
0.002
0.001

For total vitamin D, change is from 23.9 ng/mL to 34.8 ng/mL; for bioavailable vitamin D, change is from 0.84 ng/mL to 1.94 ng/mL; and for free vitamin D, change is from 2.93
pg/mL to 5.96 pg/mL
Adjusted model includes age, sex, race, and Hispanic ethnicity.
b
a

FIGURE 3. Predicted mean PUCAI with 95% confidence bands versus observed vitamin D fraction. Results are from linear regression models of log10
of vitamin D fraction, adjusted for age, race, sex, and Hispanic ethnicity (n = 384). Log10 bioavailable vitamin D was modeled as a restricted cubic
spline with 5 knots. Figure 2 demonstrates no association between PUCAI and total 25(OH)D, an association between bioavailable 25(OH)D and
PUCAI, and an association between free 25(OH)D and PUCAI.

patients.15,16 In another cross-sectional study, vitamin D deficiency was detected in 62% of IBD patients.17 Veit et al reported
18 UC patients of whom 83% had a total vitamin D less than
30 ng/mL and 50% less than 20 ng/mL.10 In an inception cohort
of 21 patients with UC, El-Matary et al reported a mean level
of total 25(OH)D of 22.8 ng/mL.18 Our study is therefore consistent with these prior reports documenting a high prevalence
of total 25(OH)D insufficiency and deficiency in UC.
We did not find any evidence that total 25(OH)D concentration was related to classic laboratory or clinical measures
of disease activity including albumin, hemoglobin, CRP/ESR,
or PUCAI. Multiple cross-sectional pediatric studies have
demonstrated an association of total vitamin D to ESR, but
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not albumin.10,15,16,19 Our study did not show this association
between vitamin D and ESR, although it should be noted that
our study population is an inception cohort with high median
ESR whereas previous studies were cross-sectional studies with
much lower inflammatory markers. A small, inception UC
cohort of 21 patients demonstrated no association between
total vitamin D and PUCAI or albumin as does our study, but
the limited sample size of that cohort likely led to underpowered tests of association between total vitamin D and laboratory and clinical measures of disease activity.18
Although we found no association between plasma
total 25(OH)D and disease activity, bioavailable 25(OH)
D was univariately associated with classic measures of
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disease activity including albumin, hemoglobin, ESR, CRP,
and PUCAI. Bioavailable 25(OH)D includes free vitamin D
and albumin-bound vitamin D, thus, one would expect an association between bioavailable 25(OH)D and albumin, as was
demonstrated in our study as well as others. Only 1 previous
study has evaluated bioavailable 25(OH)D compared to laboratory measures of disease activity in a small cohort of adult
CD and UC patients on therapy.11 A potential limitation of that
study was that free 25(OH)D was not directly measured, and so
bioavailable 25(OH)D was calculated from a less precise measure of VDBP using a monoclonal assay.20 Their study was not
able to identify a correlation between bioavailable 25(OH)D and
CRP, but did find evidence for a correlation with both albumin
and platelets. Interestingly, bioavailable 25(OH)D was inversely
correlated with clinical disease activity in UC defined by the
Simple Clinical Colitis Activity Index, similar to our study.11
In our descriptive analyses, we found no statistically
significant associations between bioavailable vitamin D and
objective measures of mucosal inflammation including Mayo
subscore and fecal calprotectin. Meckel et al demonstrated
an association between total 25(OH)D and Mayo endoscopy
score,21 and Garg et al that total, free, and bioavailable 25(OH)
D were inversely correlated with fecal calprotectin.11 In both of
these studies a vast majority of patients were in clinical and/or
endoscopic remission. In a study of CD fecal calprotectin was
associated with low serum 25(OH)D in patients in remission
but not in patients with active disease.22 Our findings are thus
similar to this small study of active CD and suggest further
exploration is necessary in a group with a more diverse range
of disease activity.
We suggest that the reason free and bioavailable vitamin D
did not predict mucosal disease as measured by Mayo score or
calprotectin is due primarily to the low frequency of mild endoscopic severity (13%) in this cohort, and potentially interreader
variability in the Mayo scoring system for endoscopic severity that has been previously published.23 We observed a trend
towards an increased frequency of severe endoscopic disease,
and decreased frequency of mild endoscopic disease, in participants in the lowest tertile for bioavailable vitamin D (Table 2,
P = 0.05). However, this relationship was not significant when
testing for a difference in the frequency of mild versus moderate-to-severe endoscopic disease between the 1st and 3rd tertiles of
bioavailable vitamin D in the adjusted logistic regression analysis
(Suppl. Table 2). Likewise, regardingfecal calprotectin, our population demonstrates severe inflammation with a median fecal calprotectin over 2000 mcg/g, recognizing that there is less power for
discrimination in our population. We will have the opportunity
to test these relationships in future studies of mucosal healing at
the week 52 time point with a more wide-range of endoscopic
activity and fecal calprotectin measurements.
We demonstrated excellent correlation between bioavailable and free 25(OH)D. This finding is expected since
bioavailable vitamin D includes free 25(OH)D in addition to

Free and Bioavailable 25-Hydroxyvitamin D Concentrations are Associated

albumin-bound vitamin D. We demonstrated only low or moderate correlation between total vitamin D and bioavailable
vitamin D, which was expected given that on average only 4.7%
of the total vitamin D was bioavailable. A majority of total
vitamin D is bound to VDBP, and VDBP is highly variable,
being predominantly driven by 2 well-known genetic polymorphisms.13 It is not known whether VDBP production or binding
affinity is altered in active inflammation or if VDBP is lost in
the stool similar to albumin and other proteins. If so, this could
have a profound effect upon the bioavailable vitamin D pool,
which would vary significantly in inflamed and noninflamed
states.
A particular strength of our study is that it is the first to
directly measure free 25(OH)D, rather than calculate it from
total vitamin D and VDBP. This is an important distinction,
given limitations of current VDBP assays and the fact that
the concentration and measurement of VDBP can be vastly
different based on race and 2 well-known genetic polymorphisms.13,20,24,25 Garg et al reported an adult UC cohort with
mild disease with mean total 25(OH)D of 28 ng/mL similar to
our population and mean bioavailable 25(OH)D of 3.6 ng/mL,
which is significantly higher than our population of 1.3 ng/ml.
It is likely that differences in direct measurement versus calculation are responsible for this dissimilarity, which would in turn
be expected to have a profound effect upon tests for associations with measures of disease activity.11 Additional strengths
of our study include a large cohort of newly diagnosed and
treatment naive patients. Finally, we provided both clinical and
laboratory measures of activity and modeled the relationships
between vitamin D fractions and disease activity when needed.
Our study was limited by the inability to infer causal effects
of bioavailable vitamin D on colitis activity. Such an inference
would require additional randomized controlled trials. We also
had a relatively small number of nonwhite participants. In addition, given that this is a study of newly diagnosed pediatric
UC patients, our sample included primarily moderate-to-severe
clinical and mucosal disease activity, which does not represent a
typical patient population on therapy with greater variation in
mucosal inflammation and disease activity. Finally, neither did
we collect dietary information on vitamin D intake nor do we
have healthy controls data.
Taken together, we suggest that our finding support the
hypothesis that bioavailable 25(OH) D may exert an effect
directly on the immune system. This finding supports current
work in mouse models evaluating the effects of vitamin D on
the immune system. In mice, vitamin D has been demonstrated
to favor a Th2 differentiation of the immune system increasing
anti-inflammatory cytokines.26 In addition, Vitamin D has been
shown to inhibit dendritic cell maturation, reducing proinflammatory cytokines.27 Thus, vitamin D deficiency has been associated with decreased anti-inflammatory cytokines and increased
proinflammatory cytokines, leading to the hypothesis that low
vitamin D may be associated with an increased inflammatory
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state. In addition to regulation of the inflammatory state, vitamin D also may have a role in gut epithelial wound healing and
permeability, because VDR deficient mice have increased susceptibility to chemically induced inflammation28,29 Altogether,
these mechanistic studies in transgenic mice have established
a direct role for vitamin D in regulating critical epithelial and
immune functions involved in IBD pathophysiology.
In summary, we confirmed the high prevalence of vitamin D deficiency and insufficiency in pediatric UC at diagnosis.
Bioavailable but not total 25(OH)D was statistically significantly associated with clinical symptoms (PUCAI) in regression models, and we found similar univariate relationships
between these vitamin D fractions and laboratory measures of
disease activity in descriptive analyses. We suggest that there
was sufficient evidence that bioavailable vitamin D is likely
involved in disease activity. Additional studies are needed to
further explore the mechanisms linking bioavailable vitamin D
to UC pathophysiology.

SUPPLEMENTARY DATA
Supplementary data are available at Inflammatory Bowel
Diseases online.
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